Novo Nordisk has launched the first GLP-1 weight-loss pill in the US, intensifying competition. The once-daily Wegovy pill is priced well below injectable versions, accelerating a sector-wide price war. It is the first approved pill that mimics the GLP-1 hormone to reduce appetite. Self-paying patients can access the starting dose for $149 a month, or $5 a day. Higher doses will rise to between $199 and $299 monthly. Insured patients may pay as little as $25 a month. Analysts say prices are far lower than typical $1,000-a-month injections. The launch lifted Novo’s shares despite strong rivalry from Eli Lilly. The pill is now available in major US pharmacies and telehealth platforms. Regulators in the UK are reviewing approval later this year.
Novo Nordisk Unveils Wegovy Weight-Loss Pill in US at Lower Price
Andrew Rogers
Andrew Rogers is a freelance journalist based in the USA, with over 10 years of experience covering Politics, World Affairs, Business, Health, Technology, Finance, Lifestyle, and Culture. He earned his degree in Journalism from the University of Florida. Throughout his career, he has contributed to outlets such as The New York Times, CNN, and Reuters. Known for his clear reporting and in-depth analysis, Andrew delivers accurate and timely news that keeps readers informed on both national and international developments.
Add A Comment
Important Links
Latest News
Outback Gazette delivers trusted news, stories, and insights from Nicosia and beyond. Stay informed with timely updates on business, lifestyle, culture, and community — your daily source for reliable information.
© 2026 Outback Gazette . All Rights Reserved.